5P - Lipid profiles of young Chinese breast cancer after adjuvant chemotherapy

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer
Presenter Winnie Yeo
Citation Annals of Oncology (2015) 26 (suppl_3): 1-3. 10.1093/annonc/mdv113
Authors W. Yeo1, C.H. Yip2, F.K. Mo2, E. Pang2, C.C. Yip2, K.M. Lee3, V. Chan3, J.J. Suen3, W.M. Ho3, T.G. Liem2
  • 1Clinical Oncology, The Chinese University of Hong Kong, SAR - Shatin/HK
  • 2Clinical Oncology, The Chinese University of Hong Kong, Shatin/HK
  • 3Clinical Oncology, Prince of Wales Hospital, Shatin/HK

Abstract

Body

Background: Among young Asian women with early stage breast cancer, there is limited data on the incidence of dyslipidemia for those who have received adjuvant chemotherapy.

Patients and methods: Patients with early stage breast cancer were recruited into this cross-sectional study. Eligibility criteria include stage I-III breast cancer diagnosis, Chinese ethnicity, age younger than 45 years at diagnosis of breast cancer and having received adjuvant chemotherapy. At the time of study entry, lipids profile was checked for individual patient. Clinical data on the menstrual history prior to and after adjuvant treatment was collected at recruitment. Menopausal status was confirmed by the individual's history and hormonal profiles.

Results: 106 patients were recruited. 96.9% of patients stopped menstruation within 1 year after completion of their adjuvant chemotherapy. 68% of patients became postmenopausal, 25% remained premenopausal and 7% were perimenopausal at recruitment. Abnormalities in lipids profile among patients who were postmenopusal vs. those who were pre/peri-menopausal were: total cholesterol >5.2 mmol/L (35.8% vs. 15.6%, p= 0.04), LDL cholesterol >2.6 mmol/L (7.46% vs. 6.25%, p= 0.8257), HDL cholesterol <1.3 mmol/L (16.42%vs. 9.38%, p= 0.3469), triglylceride > 1.7 mmol/L (17.9% vs. 3.1%, p= 0.04).

Conclusion: Among Chinese breast cancer patients who had received adjuvant chemotherapy, there was a significant proportion that developed dyslipidemia. Patients who had menopause had a high incidence of dyslipidemia than those who were pre/peri-menopausal after adjuvant chemotherapy. Breast cancer patients who undergo adjuvant chemotherapy may benefit from early detection and intervention of dyslipidemia to prevent co-morbidities.

Acknowledgement: This study was supported in part by Hong Kong Cancer Fund.

Disclosure: All authors have declared no conflicts of interest.